# Case Report: Upper extremity deep vein thrombosis revealing an occult invasive ductal breast carcinoma

**Authors:** Stefan Chiorescu, Ruxandra Oiegar, Mihaela Mocan, Mihaela Trif, Razvan Alexandru Ciocan, Roxana Mihaela Chiorescu

PMC · DOI: 10.3389/fcvm.2026.1742549 · Frontiers in Cardiovascular Medicine · 2026-02-03

## TL;DR

A rare case of upper limb deep vein thrombosis led to the discovery of an undetected breast cancer, highlighting the importance of early recognition for better outcomes.

## Contribution

This case report highlights an atypical presentation of breast cancer revealed by upper extremity thrombosis, undetectable by standard imaging.

## Key findings

- Upper limb deep vein thrombosis revealed an occult invasive lobular breast carcinoma.
- Conventional imaging failed to detect breast lesions despite elevated tumor markers.
- Therapy followed guidelines for cancer-associated thrombosis with tailored anticoagulation.

## Abstract

Deep vein thrombosis of the upper limb is a rare but clinically significant condition, as it may represent the first manifestation of an underlying malignancy and often poses diagnostic and therapeutic challenges. We present the case of a 66-year-old woman with no significant medical history, admitted for extensive deep vein thrombosis of the left upper limb that developed shortly after surgical decompression of the carpal tunnel. Postoperatively, she presented with marked swelling of the left arm, and Doppler ultrasonography confirmed thrombosis of the deep venous system. Thoracic computed tomography illustrated tumoral infiltration of the left subclavian vein and artery, causing segmental venous thrombosis and severe arterial stenosis. Despite elevated serum levels of the tumor marker Cancer Antigen 15-3, both mammography and breast ultrasonography were negative. A thoracic computed tomography–guided biopsy established the diagnosis of invasive lobular breast carcinoma, Nottingham grade 1, estrogen receptor–positive, with Ki-67 < 5%. Staging procedures included positron emission tomography combined with computed tomography, magnetic resonance imaging of the breast, and confirmatory breast biopsy. The particularity of this case lies in its atypical onset, initially mimicking carpal tunnel syndrome, combined with upper limb venous thrombosis caused by an occult breast tumor undetectable by conventional imaging but infiltrating the axillary vascular bundle. Therapeutic decisions followed international guidelines for cancer-associated thrombosis, with anticoagulation tailored to bleeding risk and oncologic therapy individualized according to the tumor's immunologic profile.

Upper extremity deep vein thrombosis is frequently associated with malignancy and may represent its first clinical manifestation, as in our patient, whose axillary breast carcinoma invaded the arteriovenous structures without detectable breast lesions. Early recognition of this condition is essential for timely diagnosis and improved prognosis. Direct oral anticoagulants represent a valuable therapeutic option with multiple advantages. Their potential antineoplastic effects—particularly those of factor XI inhibitors currently under investigation—may provide additional benefits in cancer-associated thrombosis.

## Linked entities

- **Diseases:** carpal tunnel syndrome (MONDO:0007275), invasive lobular breast carcinoma (MONDO:0005051)

## Full-text entities

- **Genes:** PGR (progesterone receptor) [NCBI Gene 5241] {aka NR3C3, PR}, CCL2 (C-C motif chemokine ligand 2) [NCBI Gene 6347] {aka GDCF-2, HC11, HSMCR30, MCAF, MCP-1, MCP1}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, EREG (epiregulin) [NCBI Gene 2069] {aka EPR, ER, Ep}, GATA3 (GATA binding protein 3) [NCBI Gene 2625] {aka HDR, HDRS}, CDK6 (cyclin dependent kinase 6) [NCBI Gene 1021] {aka MCPH12, PLSTIRE}, CYP19A1 (cytochrome P450 family 19 subfamily A member 1) [NCBI Gene 1588] {aka ARO, ARO1, CPV1, CYAR, CYP19, CYPXIX}, F9 (coagulation factor IX) [NCBI Gene 2158] {aka F9 p22, FIX, HEMB, P19, PTC, THPH8}, PGP (phosphoglycolate phosphatase) [NCBI Gene 283871] {aka AUM, G3PP, PGPase}, CXCL8 (C-X-C motif chemokine ligand 8) [NCBI Gene 3576] {aka GCP-1, GCP1, IL8, LECT, LUCT, LYNAP}, PROC (protein C, inactivator of coagulation factors Va and VIIIa) [NCBI Gene 5624] {aka APC, PC, PROC1, THPH3, THPH4}, F5 (coagulation factor V) [NCBI Gene 2153] {aka FVL, PCCF, RPRGL1, THPH2, fV}, F7 (coagulation factor VII) [NCBI Gene 2155] {aka SPCA}, ERBB2 (erb-b2 receptor tyrosine kinase 2) [NCBI Gene 2064] {aka CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19}, SERPINC1 (serpin family C member 1) [NCBI Gene 462] {aka AT3, AT3D, ATIII, ATIII-R2, ATIII-T1, ATIII-T2}, F3 (coagulation factor III, tissue factor) [NCBI Gene 2152] {aka CD142, TF, TFA}, F2RL1 (F2R like trypsin receptor 1) [NCBI Gene 2150] {aka GPR11, PAR2}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, F11 (coagulation factor XI) [NCBI Gene 2160] {aka FXI, PTA}, ESR1 (estrogen receptor 1) [NCBI Gene 2099] {aka ER, ESR, ESRA, ESTRR, Era, NR3A1}, CDK4 (cyclin dependent kinase 4) [NCBI Gene 1019] {aka CMM3, MCPH31, PSK-J3}, F10 (coagulation factor X) [NCBI Gene 2159] {aka FX, FXA}, CYP3A4 (cytochrome P450 family 3 subfamily A member 4) [NCBI Gene 1576] {aka CP33, CP34, CYP3A, CYP3A3, CYPIIIA3, CYPIIIA4}, F2 (coagulation factor II, thrombin) [NCBI Gene 2147] {aka PT, RPRGL2, THPH1}, EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}, MUC1 (mucin 1, cell surface associated) [NCBI Gene 4582] {aka ADMCKD, ADMCKD1, ADTKD2, CA 15-3, CD227, Ca15-3}
- **Diseases:** edema (MESH:D004487), endothelial dysfunction (MESH:D014652), CAT (MESH:D009369), adenopathies (MESH:D000072281), Thrombosis and Haemostasis (MESH:D020141), pain (MESH:D010146), brachial plexus compression (MESH:D020516), gastrointestinal (GI) and pancreatic tumors (MESH:D010190), venous compression (MESH:D009408), trauma (MESH:D014947), mucosal diseases (MESH:D004194), sarcopenia (MESH:D055948), inflammation (MESH:D007249), fibrosis (MESH:D005355), basal and squamous cell carcinomas of the skin (MESH:D002294), hematologic malignancies (MESH:D019337), PE (MESH:D011655), hypoalbuminemia (MESH:D034141), Thrombophilia (MESH:D019851), VTE (MESH:D014647), supraclavicular lymphadenopathies (MESH:D008206), mucosal lesions (MESH:D009059), gastric carcinoma (MESH:D013274), obesity (MESH:D009765), Bleeding (MESH:D006470), endothelial injury (MESH:D057772), osteolytic bone lesions (MESH:D001847), malignant mediastinal teratoma (MESH:D013724), DVT (MESH:D020246), Cytotoxic (MESH:D064420), invasive lobular carcinoma (MESH:D018275), leukocytosis (MESH:D007964), Krukenberg tumor (MESH:D007725), sudden unexplained death (MESH:D003645), infections (MESH:D007239), arterial stenosis (MESH:D012078), Thrombocytopenia (MESH:D013921), venous thoracic outlet syndrome (MESH:D013901), post-thrombotic syndrome (MESH:D000094025), tumorigenic (MESH:D002471), breast lesions (MESH:D061325), RVTE (MESH:D054556), neutrophilia (MESH:C563010), anemia (MESH:D000740), epithelial disturbances (MESH:D009375), gastrointestinal and genitourinary cancers (MESH:D014565), vein thrombosis (MESH:D012170), bone metastasis (MESH:D009362), thrombosis (MESH:D013927), gastrointestinal hemorrhage (MESH:D006471), invasive ductal breast carcinoma (MESH:D018270), carpal tunnel syndrome (MESH:D002349), UEDVT (MESH:D056824), invasive (MESH:D009361), hemangiomas (MESH:D006391), oncologic (MESH:D000072716), hepatic lesions (MESH:D056486), GI and GU cancers (MESH:D005770), paresthesia (MESH:D010292), protein S (MESH:D018455)
- **Chemicals:** palbociclib (MESH:C500026), dalteparin (MESH:D017985), oxygen (MESH:D010100), enoxaparin (MESH:D017984), abelacimab (MESH:C000718976), apixaban (MESH:C522181), edoxaban (MESH:C552171), letrozol (MESH:D000077289), CARAVAGGIO (-), LMWH (MESH:D006495), ROS (MESH:D017382), xisomab 3G3 (MESH:C000656431), heparin (MESH:D006493), Rivaroxaban (MESH:D000069552)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Mutations:** G20210A, G1691A

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12911504/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12911504/full.md

## References

42 references — full list in the complete paper: https://tomesphere.com/paper/PMC12911504/full.md

---
Source: https://tomesphere.com/paper/PMC12911504